THE SAFETY CHECK LIST BEFORE STARTING HT

Similar documents
Women s Health: Managing Menopause. Jane S. Sillman, MD Assistant Professor of Medicine Harvard Medical School

The Study of Tamoxifen and Raloxifene (STAR): Questions and Answers. Key Points

Kathryn M. Rexrode, MD, MPH. Assistant Professor. Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School

Patient Education. Breast Cancer Prevention. Cancer Center

RALOXIFENE Generic Brand HICL GCN Exception/Other RALOXIFENE EVISTA Is the request for the prevention (risk reduction) of breast cancer?

Personal Data. Present Symptoms

Lessons from the WHI HT Trials: Evolving Data that Changed Clinical Practice

Summary of the risk management plan (RMP) for Duavive (conjugated oestrogens / bazedoxifene)

Elements for a Public Summary. VI.2.1 Overview of Disease Epidemiology

Elements for a Public Summary. Overview of Disease Epidemiology

Orals,Transdermals, and Other Estrogens in the Perimenopause

Chemo-endocrine prevention of breast cancer

Menopause management NICE Implementation

Breast Cancer Prevention Studies. Key Points. Breast cancer prevention studies are clinical trials (research studies conducted with

BAYLOR SCOTT & WHITE HEALTH GENETICS QUESTIONNAIRE PATIENT INFORMATION

Menopause. Medicines To Help You

My Personalized Breast Cancer Worksheet

Breast Cancer Risk Assessment and Prevention

Mammography and Other Screening Tests. for Breast Problems

Learning Objectives. Peri menopause. Menopause Overview. Recommendation grading categories

Post-menopausal hormone replacement therapy. Evan Klass, MD May 17, 2018

Genetic Risk Evaluation and Testing Program

Form 2 - Eligibility Screening

Evaluations & CE Credits

Patient Information. Name: (Last) (First) (Middle) Address: (Street) (City) (State) (Zip) Home Phone: Cell Phone: address:

Imvexxy (estradiol) NEW PRODUCT SLIDESHOW

Female Patient Questionnaire & History

MENOPAUSE. I have no disclosures 10/11/18 OBJECTIVES WHAT S NEW? WHAT S SAFE?

MENOPAUSAL HORMONE THERAPY 2016

Why do I need any hormone replacement? What is Menopause? What symptoms are treated by estrogen Injections?

OVERVIEW OF MENOPAUSE

BREAST CANCER d an BREAST SELF EXAM

Patient education for transgender feminizing hormone therapy

Estrogen and progestogen therapy in postmenopausal women

Effective Health Care Program

Female Patient Questionnaire & History

INSURANCE DISCLAIMER

Hereditary Cancer Risk Program

HRT in Perimenopausal Women. Dr. Rubina Yasmin Asst. Prof. Medicine Dhaka Dental College

Breast Cancer How to reduce your risk

Evaluation & Management of PowerPoint Cover Title. the High Risk Population. High Risk Clinic

Palm Beach Obstetrics & Gynecology, PA

BREAST CANCER RISK REDUCTION

Hormonal Therapies for Breast Cancer. Westmead Breast Cancer Institute

Cancer Reference Information

Menopause Symptoms and Management: After Breast Cancer

Evolve180 / Ideal Northwest Health Profile

Real life issues & answers: The hormonal patient Defining best practice, 5 key issues & case study

Ohio Northern University HealthWise. Authors: Alexis Dolin, Andrew Duska, Hannah Lamb, Eric Miller, Pharm D Candidates 2018 May 2018

Progesterone. What is progesterone? Important information. Before taking this medicine

Menopausal hormone therapy currently has no evidence-based role for

Difference between vagifem and yuvafem

Controversies in Primary Care Pros and Cons of HRT on patients with CHD

Menopausal Symptoms. Hormone Therapy Products Available in Canada for the Treatment of. Physician Desk Reference - 3rd Edition

WHI - Volume 3, Form 32 - Family History Questionnaire (Ver. 3) Page 1. Self-administered; 12-page booklet; data entered at Clinical Center (CC).

INFORMED CONSENT FOR FEMINIZING HORMONE THERAPY

22/09/2014. Menopause Management. Menopause. Menopause symptoms

Trust Women Seattle Client Information for Informed Consent MASCULIZING MEDICATIONS FOR TRANSGENDER CLIENTS

Disclosures. Objec7ves 9/9/15. What Exactly are bio- iden7cal hormones and what should I tell my pa7ents? Christy Blanco, DNP, RN, WHNP- BC.

North American Menopause Society (NAMS)

Information on Testosterone Therapy

Top Tier. Medical Breast Specialist, P.C.

Liver Health: Do you have liver problems? Yes No If so, please specify:

Surgery to reduce the risk of ovarian cancer

Patient education for transgender masculinizing hormone therapy

Surgery to Reduce the Risk of Ovarian Cancer. Information for Women at Increased Risk

The Estrogen Question

By J. Jayasutha Lecturer Department of Pharmacy Practice SRM College of Pharmacy SRM University

presents with Ken Sekine, MD

Screening Mammograms: Questions and Answers

Cancer Genetics Baylor All Saints Medical Center at Fort Worth

Appendix: Reference Table of HT Brand Names

5. Summary of Data Reported and Evaluation

OB/GYN Update: Menopausal Management What Does The Evidence Show? Rebecca Levy-Gantt D.O. PremierObGyn Napa Inc.

Overview of disease epidemiology

PATIENT INFORMATION. (Last) (First) (Middle) (Last) (City) (State) (Zip)

WHI Estrogen--Progestin vs. Placebo (Women with intact uterus)

Confirmed blood clot

Patient Name Date of Birth Age. Other phone ( ) . Other

Before you prescribe

Most women will experience symptoms of

What You Need to Know About. Breast Cancer. At Every Age. Partners for your health.

CLINICIAN INTERVIEW CARDIOVASCULAR DISEASE IN POSTMENOPAUSAL WOMEN

What are the risk factors for breast cancer?

For Immediate Release

F REQUENTLY A SKED Q UESTIONS

Extended Adjuvant Endocrine Therapy

Breast Cancer. Common kinds of breast cancer are

LET S START WITH (AND REMEMBER WE ARE TALKING ABOUT LOCAL E2) THERAPUTIC AGENTS: ARE THEY SAFE? Systemic HT/ET. Ospemifene. Local Estrogen Therapy

POSITION PAPER FOR HEALTH CARE PROVIDERS Use of Pharmacologic Intervention for Breast Cancer Risk Reduction

RVP Medical Director Anthem Blue Cross. Provider Clinical Liaison, Oncology Solutions

Menopause and HRT. John Smiddy and Alistair Ledsam

Menopausal Management: What Has Changed?

HORMONE REPLACEMENT THERAPY

Population: All participants Number of Obs: Variable # Sas Name: Sas Label: Categories: Variable # Sas Name: F2VNUM. Sas Label: Categories:

SUSQUEHANNA HEALTH CANCER CENTER HEMATOLOGY & ONCOLOGY NEW PATIENT HEALTH QUESTIONNAIRE. Name: Date of Birth:

Menopause and HIV. Together, we can change the course of the HIV epidemic one woman at a time.

Transcription:

THE SAFETY CHECK LIST BEFORE STARTING HT This safety checklist was designed by the Endocrine Society in 2015 to minimize the chance of giving hormone therapy to women who may be negatively affected by it. The check list has 4 boxes in reference to estrogen, with one added in reference to progesterone. Please answer the questions below, and keep going down if in each individual box the answer is good. ARE YOU AT THE RIGHT AGE? The so-called Window of Opportunity is age below 60 or 10 years from your last period. Hormone therapy is likely to reduce the risk of heart disease, while it has been shown to increase the chance of heart disease if started after 60 YES Yes CONSIDERED CIRCUMSTANCES WHERE HORMONES ARE NOT A GOOD IDEA. These are called Contraindications. NONE EVALUATE RISK OF HEART ATTACK/STROKE. Use NAMS or American College of Cardiology App. Cholesterol values (and Blood pressure) are needed. LOW - MEDIUM EVALUATE RISK OF BREAST CANCER. Use the online tool created by the National Cancer Institute called Breast Cancer Risk Assessment Tool. LOW - MEDIUM In the next few pages, I will discuss how to complete the question asked in each box, and the tools at our disposal. Knowing the cholesterol levels and blood pressure is required. PREVENTING UTERINE CANCER. In women who have a uterus, adding the correct dose and type of progesterone is very important.

CIRCUMSTANCES WHERE HORMONES MAY NOT BE A GOOD IDEA CONTRAINDICATIONS TO HORMONE THERAPY There are situations when adding hormone therapy, even for women who have severe menopausal symptoms, may not be a good idea. The classical example is breast cancer. If you had, or have any of the conditions below, there are non-hormonal options. Have you ever had, or have, any of these illnesses? ABSOLUTE CONTRAINDICATIONS (when HT is practically a no, no) Breast cancer Stroke or mini stroke (Transient Ischemic attack - TIA) Hypertension (high blood pressure), not controlled my medications Heart attack (Myocardial Infarction, MI) Blood clot in leg or lungs (Venous Thromboembolism, Pulmonary Emboli VTE, DVT, PE) Known blood clotting disorder RELATIVE CONTRAINDICATIONS (HT can be used with caution) Liver disease (depending on the type and severity) Uterine cancer (endometrial) Abnormal vaginal bleeding (until explained and treated) High triglycerides Gallbladder disease Increased risk of heart disease (see NAMS, MenoPro app, ACC/AHA)) Increased risk of breast cancer (see breast cancer risk assessment tool) Migraine with aura Diabetes Please note that some of these conditions preclude estrogen administration completely (the absolute ones), such as previous breast cancer, stroke, heart disease, but others may preclude one route, for example, with gallbladder or liver disease, you can still use the creams or gels (transdermal route) but not the oral pills.

CALCULATING THE RISK OF HEART DISEASE There are many different calculators, either online or as an App, that when given a certain information, will provide a risk estimation (low, intermediate or high). The classical ones are the Framingham, Reynolds and the American College of Cardiology (ACC/AHA). I use the later because it is integrated with an App called MenoPro (by the North American Menopause Society), that also give advice about menopause. The questions asked by the ACC/AHA calculator are: 1. How old are you? years 2. Have you ever been treated for high blood pressure? Yes No 3. Have you ever been treated for diabetes? Yes No 4. Do you smoke? Yes No 5. What is your race? African American Other TO BE COMPLETED BY THE PHYSICIAN 6. Blood pressure mmhg 11. Total cholesterol mg/dl HDL mg/dl After the information is entered, the program will calculate the risk of heart disease. The results are shown as a 10 year risk, comparing to women of the same age. If you are low, or even intermediate risk, using hormones is usually safe, as long as the other parameters are also low or absent. Your risk is

CALCULATING THE RISK OF BREAST CANCER The Breast Cancer Risk Assessment Tool is an online interactive tool designed by scientists at the National Cancer Institute (NCI) and the National Surgical Adjuvant Breast and Bowel Project (NSABP) to estimate a woman's risk of developing invasive breast cancer. The survey includes 8 questions that can be completed online (https://www.cancer.gov/bcrisktool) or below. Please answer the 5 questions below (there are 3 others such as your, such as your age): 1. How old were you when you had your first period? years 2. How old were you when you had your first live birth of a child? years 3. Do you have a history of any of the following? o Breast cancer? Yes No o Ductal carcinoma in situ? Yes No o Lobular carcinoma in situ? Yes No o Hodgkin lymphoma of the chest? Yes No o BRCA1 or BRCA 2 gene? Yes No o Any genetic syndrome? Yes No o A breast biopsy? Yes No o How many biopsies have you had? o Did biopsy show atypical hyperplasia? Yes No 4. How many first-degree relatives (mother, sisters, daughters only) have had breast cancer? One Two Three More 5.What is your race/ethnicity? (Apologies for asking this question) After the information is entered, the program will calculate the risk of breast cancer. The results are shown as a 5-year risk and lifetime risk, comparing to women of the same age. Below are the 5-year calculations. If you are low, or even intermediate risk, using hormones is usually safe, as long as the other parameters are also low or absent.

Your risk is PREVENTING UTERINE CANCER - ADEQUATE PROGESTERONE PROTECTION All the previous questions refer to the use of estrogen. Estrogen makes the lining of the uterus, called the endometrium, to grow thicker. Estrogen is like a fertilizer to the lawn. In women who only take estrogen, the likelihood of developing endometrial cancer (uterine cancer) is markedly increased. Progesterone counteracts estrogen growth effect, working as a lawn mower. Progesterone is not necessary in women who had a hysterectomy, although some feel better using it. It may even reduce the number of hot flushes by itself. Sometimes we ll try it alone in women who had a contraindication to using estrogen, such as migraines with aura. There are many progesterone s available, in a natural or synthetic form, cream or pill versions, and different dosages. The choice of the type, route and dosage of estrogen is, however, much simpler than that of estrogen. The best one is a natural pill call micronized progesterone or Prometrium, at a dose of 100 mg orally at night on a daily basis, or 200 mg at night for 2 weeks of the month. This natural progesterone is neutral (safe), that is, it does not increase or decrease the cholesterol, or the chance of getting breast cancer. The other oral progesterone s are synthetic, and although they may be good at protecting against endometrial cancer, they may increase the cholesterol and the risk of breast cancer. Progesterone crams are not advised, as the absorption through the skin is erratic. IN A NUTSHELL Not all women need hormone treatment during or after menopause. But the decision to take HT is one of the most complex and emotional choices that women have to make in their life. My role is to help patients come to a mature decision, which can only be accomplished by education, individual evaluation, monitoring the response to the treatment, and adjust accordingly. If the check list indicates safety, then we can proceed to choose the type, dosage and route of estrogen and progesterone. Dr Roberto Leon. This information is available at www.drleon.ca.